Navigation Links
Noninvasive fecal occult blood test effective screen for lower GI tract lesions
Date:8/2/2011

221.10.254.64

The immunochemical fecal occult blood test (iFOBT) is effective for predicting lesions in the lower intestine but not in the upper gastrointestinal (GI) tract, confirms a study in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf.

The immunochemical fecal occult blood test is a useful noninvasive tool to screen for bleeding without symptoms in the lower GI tract. If bleeding is discovered, a colonoscopy is then used to investigate the source of bleeding.

Researchers from Taiwan sought to assess the specificity of iFOBT, looking at a group of 2796 people (1654 men and 1142 women) who underwent voluntary bi-directional endoscopies and an iFOBT. The mean age was 49 years. Participants underwent an iFOBT, blood tests, colonoscopy and an upper GI tract endoscopy as well as interviews. All were asymptomatic of bleeding and of major GI disorders.

In Taiwan, colorectal cancer is increasing, and ulcers and other upper GI tract issues are common. Same-day upper GI tract endoscopies and colonoscopies are commonly used to screen for cancer.

Of the total participants in the study, 397 people (14.2%) had a positive iFOBT result, indicating bleeding. The iFOBT was specific for almost 90% of colorectal cancers, adenomas and important lower GI lesions. Lower GI lesions were more common (24.1%) compared with those in the upper GI tract (17.9%). Lesions in the lower GI tract were more frequent in iFOBT-positive screens than in negative screens (41.3% versus 21.3%), whereas the frequency of lesions in the upper GI tract was similar in both positive and negative screens.

"Among participants found to have a malignant lesion, almost all who had colon cancer had a positive fecal test result (27/28, 96.4%). In contrast, none of the three participants found to have esophageal or gastric cancer had a positive fecal test result," writes Ming-Shiang Wu, Department of Internal Medicine, National Taiwan University, Taiwan, with coauthors.

"We found that the specificity of the immunochemical fecal occult blood test was almost 90% for predicting colorectal cancer, adenoma or any important lesion in the lower gastrointestinal tract. These findings support those of previous studies showing that the immunochemical fecal test is a specific diagnostic tool,"" write the authors.


'/>"/>

Contact: Dr. Ming-Shiang Wu
mingshiang@ntu.edu.tw
886-972-651-025
Canadian Medical Association Journal
Source:Eurekalert

Related medicine news :

1. New research shows innovative respiratory stress test can quickly detect significant coronary artery disease in a noninvasive setting
2. Noninvasive combination technique may reduce number of breast biopsies
3. Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer
4. Noninvasive Test for Colon Cancer Shows Promise in Early Trial
5. Noninvasive brain stimulation helps improve motor function in stroke patients
6. Noninvasive Glaucoma Test Might Speed Up Detection
7. Noninvasive test for trisomy 21 closer at hand
8. Noninvasive Test May Identify Down Syndrome Early On
9. Noninvasive extenders are better than surgery for men who want a longer penis
10. GEN reports on novel noninvasive tests for early cancer detection
11. Mayo Clinic reports new findings on noninvasive test for pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... ProRehab Physical Therapy (PRPT) is ... therapy provider for Derby City CrossFit, effective immediately. , In addition to treating ... effectively as possible, ProRehab’s sports physical therapists will work with athletes to maximize ...
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of ... I focus on preventative care with all my patients to alleviate possible future issues. I ... free to contact my office and my trained staff will assist you in any way ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
Breaking Medicine Technology: